Pharmaceutical Industry Reports Tuberculosis Drugs Market | Page 2

REPORT DESCRIPTION
Global Tuberculosis Drugs Market – Overview
Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the second largest
cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis.
Globally around 10% of latent infections develop into active tuberculosis. Infections that do not show any
symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4 million new
reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported. Based on the statistics of Center
for Disease Control and Prevention, a 1.6% increase in the number of tuberculosis cases was observed in 2015 as
compared to those reported in 2014. Though there is an increase in the number of tuberculosis cases, the incidence
rate per 100,000 persons has been around 3.0 since 2013.
In 2015, out of 580 thousand people who were eligible for multidrug resistance tuberculosis treatment, only 125
000 (20%) were registered. Five countries, namely India, China, the Russian Federation, Indonesia, and Nigeria
account for over 60% of this gap. Worldwide, the multidrug resistance tuberculosis treatment success rate was 50-
52% in 2013 and in 2015, approximately 55% of reported new tuberculosis patients had a documented HIV test
result.
The global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to witness a
CAGR of 23.4% during the forecast period (2016 – 2024).
© Coherent market Insights. All Rights Reserved